Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single pill regimen that was
approved by the FDA in February 2018 for treatment of HIV. The marketed name of the drug is
Biktarvy. In two phase 3 comparative clinical trials, including one with ABC/3TC/DTG, it was
found to be non-inferior to dolutegravir-containing regimens in terms of virologic outcomes.
B/F/TAF was also well tolerated, with few discontinuations for adverse events. As a result,
B/F/TAF is an ideal non-abacavir containing regimen to assess the effect of removing ABC on
coronary flow reserve.